CL2012000913A1 - Uso de una combinacion farmaceutica de compuestos especificos derivados de 4-morfolintieno[3,2-d]pirimidina con 3,4-difluoro-2-(2-fluoro-4-iodofenilamino)fenil)(3-hidroxi-3-((2s)piperidin-2-il)azetidin-1-il)metanona para tratar localmente un tumor solido avanzado o metastasico. - Google Patents
Uso de una combinacion farmaceutica de compuestos especificos derivados de 4-morfolintieno[3,2-d]pirimidina con 3,4-difluoro-2-(2-fluoro-4-iodofenilamino)fenil)(3-hidroxi-3-((2s)piperidin-2-il)azetidin-1-il)metanona para tratar localmente un tumor solido avanzado o metastasico.Info
- Publication number
- CL2012000913A1 CL2012000913A1 CL2012000913A CL2012000913A CL2012000913A1 CL 2012000913 A1 CL2012000913 A1 CL 2012000913A1 CL 2012000913 A CL2012000913 A CL 2012000913A CL 2012000913 A CL2012000913 A CL 2012000913A CL 2012000913 A1 CL2012000913 A1 CL 2012000913A1
- Authority
- CL
- Chile
- Prior art keywords
- advanced
- morpholinthieno
- iodophenylamino
- azetidin
- methanone
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 3
- 208000037843 metastatic solid tumor Diseases 0.000 title abstract 2
- -1 3,4-difluoro-2- (2-fluoro-4-iodophenylamino) phenyl Chemical group 0.000 title 1
- KVXUAECBDUUJKX-QMMMGPOBSA-N OC1([C@H]2NCCCC2)CN(C=O)C1 Chemical compound OC1([C@H]2NCCCC2)CN(C=O)C1 KVXUAECBDUUJKX-QMMMGPOBSA-N 0.000 title 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 title 1
- 208000037844 advanced solid tumor Diseases 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Método de tratamiento para tumores sólidos localmente avanzados o metastásicos que consiste en administrar una combinación farmacéutica que contiene un compuesto de fórmula I o II y un compuesto de fórmula III.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US25085209P | 2009-10-12 | 2009-10-12 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2012000913A1 true CL2012000913A1 (es) | 2012-09-14 |
Family
ID=43072663
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2012000913A CL2012000913A1 (es) | 2009-10-12 | 2012-04-11 | Uso de una combinacion farmaceutica de compuestos especificos derivados de 4-morfolintieno[3,2-d]pirimidina con 3,4-difluoro-2-(2-fluoro-4-iodofenilamino)fenil)(3-hidroxi-3-((2s)piperidin-2-il)azetidin-1-il)metanona para tratar localmente un tumor solido avanzado o metastasico. |
Country Status (24)
Country | Link |
---|---|
US (1) | US20110086837A1 (es) |
EP (1) | EP2488178B1 (es) |
JP (2) | JP2013507415A (es) |
KR (1) | KR101489045B1 (es) |
CN (1) | CN102740851B (es) |
AR (1) | AR078588A1 (es) |
AU (1) | AU2010314287A1 (es) |
BR (1) | BR112012008483A2 (es) |
CA (1) | CA2776944A1 (es) |
CL (1) | CL2012000913A1 (es) |
CO (1) | CO6531463A2 (es) |
CR (1) | CR20120173A (es) |
EC (1) | ECSP12011865A (es) |
ES (1) | ES2609767T3 (es) |
HK (1) | HK1175125A1 (es) |
IL (1) | IL219105A0 (es) |
MA (1) | MA33974B1 (es) |
MX (1) | MX345155B (es) |
NZ (1) | NZ599939A (es) |
PE (1) | PE20121816A1 (es) |
RU (1) | RU2563193C2 (es) |
TW (1) | TWI428336B (es) |
WO (1) | WO2011054620A1 (es) |
ZA (1) | ZA201202618B (es) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20110105521A1 (en) | 2008-07-11 | 2011-05-05 | Novartis Ag | Combination of (a) a phosphoinositide 3-kinase inhibitor and (b) a modulator of ras/raf/mek pathway |
KR101430424B1 (ko) | 2009-01-08 | 2014-08-14 | 쿠리스 인코퍼레이션 | 아연 결합 모이어티를 갖는 포스포이노시티드 3-키나제 억제제 |
EP2519526B1 (en) | 2009-12-31 | 2014-03-26 | Centro Nacional de Investigaciones Oncológicas (CNIO) | Tricyclic compounds for use as kinase inhibitors |
WO2012098387A1 (en) | 2011-01-18 | 2012-07-26 | Centro Nacional De Investigaciones Oncológicas (Cnio) | 6, 7-ring-fused triazolo [4, 3 - b] pyridazine derivatives as pim inhibitors |
RS54903B1 (sr) | 2011-04-01 | 2016-10-31 | Curis Inc | Inhibitor fosfoinozitid 3 kinaze sa delom koji vezuje cink |
WO2013019906A1 (en) | 2011-08-01 | 2013-02-07 | Genentech, Inc. | Methods of treating cancer using pd-1 axis binding antagonists and mek inhibitors |
WO2013066483A1 (en) * | 2011-08-31 | 2013-05-10 | Novartis Ag | Synergistic combinations of pi3k- and mek-inhibitors |
EP2766011B1 (en) | 2011-10-13 | 2017-09-27 | Genentech, Inc. | Treatment of pharmacological-induced hypochlorhydria in cancer patients |
CN104039340B (zh) * | 2011-10-28 | 2017-04-05 | 霍夫曼-拉罗奇有限公司 | 治疗黑素瘤的方法及治疗剂组合 |
WO2013082511A1 (en) | 2011-12-02 | 2013-06-06 | Genentech, Inc. | Methods for overcoming tumor resistance to vegf antagonists |
PE20142020A1 (es) * | 2012-04-06 | 2014-12-24 | Sanofi Sa | Metodos para tratar el cancer usando inhibidor de pi3k e inhibidor de mek |
WO2013157648A1 (ja) * | 2012-04-19 | 2013-10-24 | 国立大学法人九州大学 | 医薬組成物 |
AU2013273489B9 (en) | 2012-06-08 | 2018-08-23 | F. Hoffmann-La Roche Ag | Mutant selectivity and combinations of a phosphoinositide 3 Kinase inhibitor compound and chemotherapeutic agents for the treatment of cancer |
US9463251B2 (en) | 2012-08-02 | 2016-10-11 | Genentech, Inc. | Anti-ETBR antibodies and immunoconjugates |
MX2015001399A (es) | 2012-08-02 | 2015-09-07 | Genentech Inc | Anticuerpos anti-etbr e inmunoconjugados. |
SG10201708494QA (en) * | 2012-08-17 | 2017-11-29 | Hoffmann La Roche | Combination therapies for melanoma comprising administering cobimetinib and vemurafinib |
JP2016515132A (ja) * | 2013-03-14 | 2016-05-26 | ジェネンテック, インコーポレイテッド | Mek阻害剤化合物のher3/egfr阻害剤化合物との組み合わせ及び使用方法 |
US9532987B2 (en) | 2013-09-05 | 2017-01-03 | Genentech, Inc. | Use of a combination of a MEK inhibitor and an ERK inhibitor for treatment of hyperproliferative diseases |
ES2779975T3 (es) | 2014-02-07 | 2020-08-21 | Verastem Inc | Métodos y composiciones para tratar el crecimiento celular anormal |
EP3169361B1 (en) | 2014-07-15 | 2019-06-19 | F.Hoffmann-La Roche Ag | Compositions for treating cancer using pd-1 axis binding antagonists and mek inhibitors |
CN113620978A (zh) * | 2014-09-11 | 2021-11-09 | 加利福尼亚大学董事会 | mTORC1抑制剂 |
EP3849554A4 (en) | 2018-09-11 | 2022-06-01 | Curis, Inc. | POLYTHERAPY WITH A PHOSPHOINONOSITIDE 3-KINASE INHIBITOR HAVING A ZINC-BINDING METAL |
CN110420330B (zh) * | 2019-07-19 | 2020-05-29 | 南京医科大学 | 一种pi3k与mth1靶向药组合物的制药用途 |
WO2021047783A1 (en) | 2019-09-13 | 2021-03-18 | The Institute Of Cancer Research: Royal Cancer Hospital | Vs-6063 in combination with ch5126766 for the treatment of cancer |
US11873296B2 (en) | 2022-06-07 | 2024-01-16 | Verastem, Inc. | Solid forms of a dual RAF/MEK inhibitor |
Family Cites Families (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE1470356A1 (de) * | 1964-01-15 | 1970-04-30 | Thomae Gmbh Dr K | Neue Thieno[3,2-d]pyrimidine und Verfahren zu ihrer Herstellung |
BE754606A (fr) * | 1969-08-08 | 1971-02-08 | Thomae Gmbh Dr K | Nouvelles 2-aminoalcoylamino-thieno(3,2-d)pyrimidines et leurs procedesde fabrication |
BE759493A (fr) * | 1969-11-26 | 1971-05-25 | Thomae Gmbh Dr K | Nouvelles 2-(5-nitro-2-furyl)-thieno(3,2-d) pyrimidines et procedes pour les fabriquer |
US3763156A (en) * | 1970-01-28 | 1973-10-02 | Boehringer Sohn Ingelheim | 2-heterocyclic amino-4-morpholinothieno(3,2-d)pyrimidines |
CH592668A5 (es) * | 1973-10-02 | 1977-10-31 | Delalande Sa | |
GB1570494A (en) * | 1975-11-28 | 1980-07-02 | Ici Ltd | Thienopyrimidine derivatives and their use as pesticides |
US4510139A (en) * | 1984-01-06 | 1985-04-09 | Sterling Drug Inc. | Substituted aminobenzamides and their use as agents which inhibit lipoxygenase activity |
WO1995026956A1 (fr) * | 1994-04-01 | 1995-10-12 | Shionogi & Co., Ltd. | Derive d'oxime et bactericide le contenant en tant qu'ingredient actif |
US6974878B2 (en) * | 2001-03-21 | 2005-12-13 | Symyx Technologies, Inc. | Catalyst ligands, catalytic metal complexes and processes using same |
US6608053B2 (en) * | 2000-04-27 | 2003-08-19 | Yamanouchi Pharmaceutical Co., Ltd. | Fused heteroaryl derivatives |
US7498304B2 (en) * | 2000-06-16 | 2009-03-03 | Curis, Inc. | Angiogenesis-modulating compositions and uses |
YU2503A (sh) * | 2000-07-19 | 2006-05-25 | Warner-Lambert Company | Oksigenovani estri 4-jodo fenilamino benzhidroksamskih kiselina |
US7235537B2 (en) * | 2002-03-13 | 2007-06-26 | Array Biopharma, Inc. | N3 alkylated benzimidazole derivatives as MEK inhibitors |
WO2004078116A2 (en) * | 2003-03-03 | 2004-09-16 | Array Biopharma, Inc. | P38 inhibitors and methods of use thereof |
US20050049276A1 (en) * | 2003-07-23 | 2005-03-03 | Warner-Lambert Company, Llc | Imidazopyridines and triazolopyridines |
US7144907B2 (en) * | 2003-09-03 | 2006-12-05 | Array Biopharma Inc. | Heterocyclic inhibitors of MEK and methods of use thereof |
US7538120B2 (en) * | 2003-09-03 | 2009-05-26 | Array Biopharma Inc. | Method of treating inflammatory diseases |
EP1674452A4 (en) * | 2003-09-19 | 2007-10-10 | Chugai Pharmaceutical Co Ltd | NOVEL 4-PHENYLAMINO-BENZALDOXIME DERIVATIVE AND ITS USE AS MEK INHIBITOR |
US7517994B2 (en) * | 2003-11-19 | 2009-04-14 | Array Biopharma Inc. | Heterocyclic inhibitors of MEK and methods of use thereof |
GB0423653D0 (en) | 2004-10-25 | 2004-11-24 | Piramed Ltd | Pharmaceutical compounds |
ATE504565T1 (de) * | 2005-10-07 | 2011-04-15 | Exelixis Inc | Azetidine als mek-inhibitoren bei der behandlung proliferativer erkrankungen |
UA95799C2 (en) * | 2006-04-26 | 2011-09-12 | Ф. Хоффманн-Ля Рош Аг | Pharmaceutical compounds |
JP2010500994A (ja) * | 2006-08-16 | 2010-01-14 | エグゼリクシス, インコーポレイテッド | Pi3kおよびmekモジュレーターを使用する方法 |
JP5284977B2 (ja) * | 2006-12-07 | 2013-09-11 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | ホスホイノシチド3−キナーゼ阻害剤化合物及び使用方法 |
RU2523890C2 (ru) * | 2007-09-12 | 2014-07-27 | Дженентек, Инк. | Комбинации ингибиторов фосфоинозитид 3-киназы и химиотерапевтических агентов и способы применения |
JP6147246B2 (ja) * | 2011-04-01 | 2017-06-14 | ジェネンテック, インコーポレイテッド | Akt及びmek阻害剤化合物の組み合わせ、及び使用方法 |
-
2010
- 2010-10-11 CA CA2776944A patent/CA2776944A1/en not_active Abandoned
- 2010-10-11 CN CN2010800563069A patent/CN102740851B/zh not_active Expired - Fee Related
- 2010-10-11 AU AU2010314287A patent/AU2010314287A1/en not_active Abandoned
- 2010-10-11 JP JP2012533589A patent/JP2013507415A/ja not_active Ceased
- 2010-10-11 WO PCT/EP2010/065149 patent/WO2011054620A1/en active Application Filing
- 2010-10-11 NZ NZ599939A patent/NZ599939A/en not_active IP Right Cessation
- 2010-10-11 RU RU2012118974/15A patent/RU2563193C2/ru not_active IP Right Cessation
- 2010-10-11 ES ES10768448.2T patent/ES2609767T3/es active Active
- 2010-10-11 EP EP10768448.2A patent/EP2488178B1/en active Active
- 2010-10-11 MX MX2012004286A patent/MX345155B/es active IP Right Grant
- 2010-10-11 PE PE2012000470A patent/PE20121816A1/es not_active Application Discontinuation
- 2010-10-11 US US12/902,062 patent/US20110086837A1/en not_active Abandoned
- 2010-10-11 BR BR112012008483A patent/BR112012008483A2/pt not_active IP Right Cessation
- 2010-10-11 KR KR1020127012069A patent/KR101489045B1/ko not_active IP Right Cessation
- 2010-10-11 TW TW099134615A patent/TWI428336B/zh not_active IP Right Cessation
- 2010-10-11 MA MA34821A patent/MA33974B1/fr unknown
- 2010-10-12 AR ARP100103706A patent/AR078588A1/es not_active Application Discontinuation
-
2012
- 2012-04-05 IL IL219105A patent/IL219105A0/en unknown
- 2012-04-10 CR CR20120173A patent/CR20120173A/es unknown
- 2012-04-11 ZA ZA2012/02618A patent/ZA201202618B/en unknown
- 2012-04-11 CL CL2012000913A patent/CL2012000913A1/es unknown
- 2012-04-20 CO CO12065784A patent/CO6531463A2/es not_active Application Discontinuation
- 2012-05-03 EC ECSP12011865 patent/ECSP12011865A/es unknown
-
2013
- 2013-03-04 HK HK13102634.3A patent/HK1175125A1/xx not_active IP Right Cessation
-
2014
- 2014-10-01 JP JP2014202819A patent/JP5745678B2/ja not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
MA33974B1 (fr) | 2013-02-01 |
ECSP12011865A (es) | 2012-06-29 |
ES2609767T3 (es) | 2017-04-24 |
AU2010314287A2 (en) | 2012-07-12 |
KR20120064132A (ko) | 2012-06-18 |
CA2776944A1 (en) | 2011-05-12 |
TW201118082A (en) | 2011-06-01 |
MX345155B (es) | 2017-01-18 |
KR101489045B1 (ko) | 2015-02-02 |
NZ599939A (en) | 2014-02-28 |
BR112012008483A2 (pt) | 2019-09-24 |
WO2011054620A1 (en) | 2011-05-12 |
US20110086837A1 (en) | 2011-04-14 |
MX2012004286A (es) | 2012-05-22 |
RU2563193C2 (ru) | 2015-09-20 |
AU2010314287A1 (en) | 2012-05-03 |
CN102740851B (zh) | 2013-12-18 |
RU2012118974A (ru) | 2013-11-20 |
ZA201202618B (en) | 2014-10-29 |
JP2013507415A (ja) | 2013-03-04 |
HK1175125A1 (en) | 2013-06-28 |
CN102740851A (zh) | 2012-10-17 |
CR20120173A (es) | 2012-07-04 |
IL219105A0 (en) | 2012-06-28 |
JP5745678B2 (ja) | 2015-07-08 |
CO6531463A2 (es) | 2012-09-28 |
PE20121816A1 (es) | 2013-01-02 |
EP2488178A1 (en) | 2012-08-22 |
EP2488178B1 (en) | 2016-11-16 |
TWI428336B (zh) | 2014-03-01 |
AR078588A1 (es) | 2011-11-16 |
JP2015038110A (ja) | 2015-02-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2012000913A1 (es) | Uso de una combinacion farmaceutica de compuestos especificos derivados de 4-morfolintieno[3,2-d]pirimidina con 3,4-difluoro-2-(2-fluoro-4-iodofenilamino)fenil)(3-hidroxi-3-((2s)piperidin-2-il)azetidin-1-il)metanona para tratar localmente un tumor solido avanzado o metastasico. | |
EA201100136A1 (ru) | 2,4'-бипиридинилы в качестве ингибиторов протеинкиназы d, применимые для лечения сердечной недостаточности и рака | |
GEP20125469B (en) | Inhibitors of akt activity | |
CY1115902T1 (el) | Συνδυαστικη θεραπεια καρκινου με ανασταλτικες ενωσεις hps90 | |
GEP20146146B (en) | Pyrrolopyrimidine compounds as inhibitors of cdk4/6 | |
DK2020996T3 (da) | Fremgangsmåder og sammensætninger til behandling af hæmatologiske sygdomme | |
JO2848B1 (en) | Organic compounds | |
BR112012026767A2 (pt) | composto, sal farmaceuticamente aceitável de um composto, composição farmacêutica, método para tratar ou previnir distúrbios, e, uso de um composto ou sal | |
BR112014017840A8 (pt) | Compostos terapeuticamente ativos, sua composição farmacêutica e seu uso | |
TR201900306T4 (tr) | Mek inhibitörlerini kullanma yöntemleri. | |
EA201391626A1 (ru) | Соединения для ингибирования клеточной пролиферации в egfr-стимулированных типах рака | |
EA200970486A1 (ru) | Соединения для ингибирования митоза | |
TN2011000053A1 (en) | Organic compounds | |
MY183014A (en) | Compounds for enzyme inhibition | |
TN2012000152A1 (en) | Spiropiperidine compounds and pharmaceutical use thereof for treating diabetes | |
NZ590550A (en) | Inhibitors of Apoptosis (IAP) for treating cancer | |
TN2011000291A1 (en) | Purine compounds | |
CL2008003041A1 (es) | Compuestos derivados de acido boronico, inhibidores de proteasoma; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del cancer. | |
DK1885187T3 (da) | Fremgangsmåde til behandling af lægemiddelresistent cancer | |
EA201200102A1 (ru) | Соединения, применимые в качестве лекарственных средств | |
NZ700612A (en) | Methods and compositions for treating ewings sarcoma family of tumors | |
MX340870B (es) | Compuestos de unión del dominio de repetición de inhibidores de proteínas de apoptosis de baculovirus. | |
EA201001196A1 (ru) | Соединения 4-пиридинона и их применение для лечения рака | |
EA201190125A1 (ru) | Таблетки для комбинированной терапии | |
MX2009009574A (es) | Tratamiento de melanoma. |